Pharmabiotech Stocks To Watch This Prostate Cancer Month | Latest News RSS feed

Pharmabiotech Stocks To Watch This Prostate Cancer Month - Latest News


Pharma/Biotech Stocks to Watch This Prostate Cancer Month

September is observed as National Prostate Cancer Month to raise awareness about the disease, which is the leading cause of death in men, second only to skin cancer in the United States. A light blue ... read more

10 Pharma Stocks To Watch This Month

Watch out for... A phase III study of 1404, a PSMA-targeted small molecule SPECT/CT imaging agent in patients with newly-diagnosed or low-grade prostate cancer, dubbed ProSPECT-AS, is underway. Top-li... read more

This Week June 20-24: Breakout Stocks to Watch and 1 Speculative Biotech

I like the long-term growth prospects of PSMT and technicals; however, my long position was not initiated until over a month after it appeared on my "Stocks to Watch This Week ... cancers such as lung ... read more

Looking for another news?


Biopharma Companies to Watch This Week

But with the risk of failure, which could spell disaster for a stock, comes great reward as well ... PSMA-617 is a radioligand therapy for the targeted treatment of prostate cancer. Shares of Endocyte ... read more


Biotech Stocks Will be Fueled by Takeovers in 2011

As an example, the stock of a company called Dendreon Corp. (DNDN) traded for years in a range of $3 to $8 a share with very little activity. Dendreon discovered a prostate cancer vaccine ... is The M... read more

What to Expect From Dendreon's Provenge

Investors should be at the ready -- any word from the FDA could tank the stock or send it soaring ... while Provenge only requires one infusion a month for three months. Prostate cancer is the second ... read more

Abolish the FDA; it’s insane

Dendreon has to charge $90,000 a month for Provenge, a prostate cancer drug ... Start with the FDA. Then come back to me for the list of other departments we can cut. Tons of people including me own s... read more

This Black Friday, Any Rally Will Be Light: Market Recon

KO was slapped with a Moody's downgrade on Tuesday afternoon and JNJ failed in a U.S. appeals court to block the expected October launch of several generic forms of the prostate cancer treatment drug, ... read more

Biotech Stocks To Watch In 2012

Exelixis (NASDAQ:EXEL) is starting to recuperate after last year's clash with the FDA regarding a registration trial for its lead agent, cabozantinib (cabo), in prostate cancer ... both had lung cance... read more

9 Pharma Stocks To Watch This Month

(RTTNews) - Biotech stocks ... cancer and prostate cancer. Watch out for… Interim safety and efficacy data from Stage 1 of the phase II clinical trial of SM-88 in metastatic pancreatic cancer, dubbed ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us